

May 1, 2024

The Honorable Brett Guthrie, Chair United States House of Representatives Committee on House Energy and Commerce 2125 Rayburn House Office Building Washington, D 20515-6115

Dear Chairman Guthrie,

The American Cancer Society Cancer Action Network appreciates the opportunity to respond to additional questions for the record for the Subcommittee on Health hearing entitled "Legislative Proposals to Support Patients and Caregivers" on Wednesday, February 14, 2024.

Please see the attached responses.

Sincerely,

Angela Sailor

Director Federal Strategic Alliances, Health Equity

Attachment — Additional Questions for the Record

The Honorable Neal Dunn, M.D.

1. Please explain why H.R. 2407, (co-sponsored by Representative Dunn and led by Representatives, Hudson, Ruiz, Arrington, and Sewell), a bill that will ensure that Medicare beneficiaries can benefit from multi-cancer early detection blood test screenings, is important for improved outcomes?

The importance of multi-cancer early detection ("MCED") tests are innovative and have the potential to detect multiple cancers at earlier stages before an individual is symptomatic. ACS CAN has endorsed the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act (H.R. 2407), which will potentially expand Medicare access to MCED tests. The legislation does not mandate that Medicare cover all MCED tests. Under the legislation, once the test has been approved by the FDA, the Centers for Medicare and Medicaid Services (CMS) could initiate an evidence-based coverage process to determine coverage when clinical benefit of the tests have been shown. The legislation does not impact Medicare's current coverage of existing screening tests for breast, cervical, colorectal, lung, and prostate cancers. Without legislation, Medicare beneficiaries could experience unacceptable delays in access to multi-cancer early detection.

The Honorable Neal Dunn, M.D.

2. Genetic counselors play an essential role when there are genetic aspects to disease and conditions. They ensure patients and family members who would benefit from genetic testing gain access to appropriate testing and ensure physicians and their patients understand test results well. Genetic counselors also help navigate follow-up care and identify clinical trials that may be of benefit. Today, Medicare does not reimburse genetic counselor services. Should this policy change?

We believe genetic counselors play an important role in helping individuals understand their risk of developing forms of cancer for which there is a genetic component. ACS CAN supports policies that would provide Medicare Part B coverage of services furnished by genetic counselors.